PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS
Public ClinicalTrials.gov record NCT06413095. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pembrolizumab Alone and in Combination(s) With MK-0482 and MK-4830 Via Intratumoral Injection in Patients With Head and Neck Squamous Cell Carcinoma or Soft Tissue Sarcoma Prior to Planned Surgical Intervention
Study identification
- NCT ID
- NCT06413095
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Early Phase 1
- Lead sponsor
- Presage Biosciences
- Industry
- Enrollment
- 13 participants
Conditions and interventions
Interventions
- Pembrolizumab Biological
- MK-0482 + Pembrolizumab Combination Product
- MK-4830 + Pembrolizumab Combination Product
Biological · Combination Product
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2022
- Primary completion
- Jun 21, 2023
- Completion
- Jun 21, 2023
- Last update posted
- May 13, 2024
2022 – 2023
United States locations
- U.S. sites
- 11
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC Davis | Sacramento | California | 95817 | — |
| Emory Winship Cancer Institute | Atlanta | Georgia | 30308 | — |
| LSU Health Sciences Center - Shreveport | Shreveport | Louisiana | 71115 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| University of North Carolina | Chapel Hill | North Carolina | 27599 | — |
| UC Health | Cincinnati | Ohio | 45219 | — |
| Oregon Health & Science University (OHSU) | Portland | Oregon | 97239 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19107 | — |
| Sarah Cannon Medical Center | Charleston | South Carolina | 29406 | — |
| UT Health Houston | Houston | Texas | 77401 | — |
| University of Washington | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06413095, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 13, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06413095 live on ClinicalTrials.gov.